Epidemiologist Harvey A. Risch, MD Advocates for Hydroxychloroquine & Zinc

Harvey A. Risch, MD, PhD, is professor of epidemiology at Yale School of Public Health.
No Comments Yet – Leave One

In This Article

  • Efficacy of HCQ when given in early-stage COVID-19 in combination with zinc and azithromycin or doxycycline.
  • Seven separate studies form the basis for Risch's call for "the immediate early use of hydroxychloroquine in high-risk patients."
  • In addition to research studies, real world examples of widespread use are cited as further evidence, such as the use of HCQ in Brazil and Switzerland.
  • Risch notes that many studies on HCQ and COVID-19 are not using HCQ correctly, either giving HCQ in toxic doses (and then reporting side effects) or giving HCQ too late in the development of COVID-19.
  • Risch debunks the notion that HCQ is dangerous, especially with regard to cardiac arrhythmia.

As professor of epidemiology at Yale School of Public Health, I have authored over 300 peer-reviewed publications and currently hold senior positions on the editorial boards of several leading journals. I am usually accustomed to advocating for positions within the mainstream of medicine, so have been flummoxed to find that, in the midst of a crisis, I am fighting for a treatment that the data fully support but which, for reasons having nothing to do with a correct understanding of the science, has been pushed to the sidelines. As a result, tens of thousands of patients with COVID-19 are dying unnecessarily. Fortunately, the situation can be reversed easily and quickly.

I am referring, of course, to the medication hydroxychloroquine. When this inexpensive oral medication is given very early in the course of illness, before the virus has had time to multiply beyond control, it has shown to be highly effective, especially when given in combination with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.

On May 27, I published an article in the American Journal of Epidemiology (AJE) entitled, "Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis." That article, published in the world's leading epidemiology journal, analyzed five studies, demonstrating clear-cut and significant benefits to treated patients, plus other very large studies that showed the medication safety.

Continue Reading at Newsweek


By: Truth About HCQ
Truth About HCQ was created to centralize and protect information related to the use of Hydroxychloroquine and HCQ treatment protocols in COVID-19 patients.